On 27 august Bangladesh government approved the trial of the COVID 19 vaccine developed by Chinese drugmaker Sinovac Biotech Ltd. The very next day Bangladesh's top drugmaker beximco pharma signed an exclusive deal with India's serum institute to get priority access to the coronavirus vaccine developed by Oxford and AstraZeneca.
Vaccine from India's Serum Institute
According to Beximco's deal with Serum institute, the Bangladeshi company invested in Indian serum institute to secure the oxfords COVID 19 vaccines on time. The investment amount will be treated as an advance and once the vaccine receives regulatory approvals, SII will include Bangladesh among the countries who will be the first to receive an agreed quantity of this vaccine from SII on a priority basis,” Beximco said in a statement. Earlier Indian foreign secretary visited Bangladesh and discussed
Vaccine from Chinese Sinovac Biotech
Bangladesh already started the trial of the Chinese Covid-19 vaccine developed by the Chinese company Sinovac Biotech Ltd. China Vaccine Company Synovac has been allowed to participate in the trial. The trial will involve 4,200 volunteers and half of them will be vaccinated. The Bangladesh government will get one lakh pieces of vaccine free of cost from Sinovac.
As Bangladesh was searching for a probable coronavirus vaccine - the promising Chinese and Indian oxford vaccine will help Bangladesh to vaccinate its people.